The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Dengue Virus VLP – Serotypes 1-4

$2,008.80 excl. VAT

Multi-pack of all Dengue Virus VLPs, containing 100ug each of VLPs from serotypes 1-4.


This Dengue VLP multi-pack has been prepared in response to many customers requesting a combination pack for the purchase of all 4 Dengue VLP serotypes. We now offer a convenient multi-pack in which 1 vial of each serotype VLP is included with a 15% discount on the price compared to ordering the products individually. This multi-pack is ideal for cross-reactivity screening and other such experiments. Each pack contains:

  • 1 vial of 100ug from strain Nauru/Western Pacific/1974.
  • 1 vial of 100ug from strain Thailand/16681/84.
  • 1 vial of 100ug from strain Sri Lanka D3/H/IMTSSA-SRI/2000/1266.
  • 1 vial of 100ug from strain Dominica/814669/1981.

These VLPs have been extensively characterised by Metz et al, (2018) showing binding of epitope specific antibodies to the VLPs, and how they can be used to deplete patient sera of serotype specific antibodies.



  • VLPs are produced in human cell lines using state-of-the-art expression techniques.
  • Constructed from E, M and preM proteins, with secretion from the cell aided by substituting the C terminal 20% with the corresponding Japanese Encephalitis Virus sequence (all internal/transmembrane).
  • Concentration and purification by a series of ultracentrifuge and chromatographical methods which result in exceptional quality and purity.
  • Cleavage of preM protein occurs naturally by furin in the cell and results in a dual population of preM and M-containing VLPs.



With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics (ref WHO for Guidelines for Diagnosis, Treatment, Prevention & Control, 2009) As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus.

Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.

Publishing research using our reagents? Please let us know so that we can cite your publication as a reference.

  • Metz et al (2018). Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J. 2018 Apr 2;15(1):60 PMID: 29609659
  • Lecouturier V et al. (2018). Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes. Vaccine. Apr 26. pii: S0264-410X(18)30562-0. PMID: 29706291
  • Goldman ER et al (2017). Bglbrick strategy for the construction of single domain antibody fusions. Heliyon. Dec 28;3(12):e00474. PMID: 29322100
  • Aurelie Deliot et al (2017) Visualization of Dengue virus like particles interacting with antibodies. The 16th European Microscopy Congress, Lyon, France.